What is TACGen?
TACGen operates at the intersection of advanced molecular biology and high-throughput genetic analysis. The company provides a comprehensive suite of essential tools, including custom cloning solutions, plasmid preparation, and sophisticated sequencing services. By catering to the rigorous demands of the research and biotechnology sectors, TACGen has established itself as a critical partner for scientists engaged in complex genetic manipulation and epigenetic modulator discovery. Their commitment to high-quality output and technical precision allows them to maintain a robust market position, serving as a foundational resource for laboratories and biotech firms seeking reliable, scalable genetic research infrastructure.
How much funding has TACGen raised?
TACGen has raised a total of $17K across 1 funding round:
Debt
$17K
Debt (2021): $17K with participation from PPP
Key Investors in TACGen
PPP
Public-Private Partnership
What's next for TACGen?
Moving into its next phase of development, TACGen is expected to leverage its recent capital injection to broaden its service portfolio and enhance its high-throughput sequencing capabilities. As the firm transitions through its Series A/B growth stage, the strategic focus will likely shift toward optimizing operational efficiencies and expanding its footprint in the epigenetic research market. By scaling its custom cloning and DNA preparation services, TACGen aims to capture a larger share of the life sciences market, providing the necessary technical agility to support emerging trends in genomic medicine and synthetic biology. Continued investment in infrastructure will be paramount to sustaining this growth trajectory and meeting the evolving needs of the global scientific community.
See full TACGen company page
